Editors:
- Provides up-to-date overview of current immunotherapeutic treatment options, strategies, and research efforts
- Discusses strategies to overcome the challenges associated with immunotherapy
- Presents cutting-edge research that may inform future developments in the field of immunotherapy
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1342)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (19 chapters)
-
Front Matter
About this book
The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist.
Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions.The fourth edition will have a new focus on strategies to overcomethe challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy.Keywords
- biomarkers
- immune checkpoint inhibitors
- resistance to therapy
- immune-related adverse events
- patient-reported outcomes
- clinical application
- diagnostic procedures
- melanoma
- lung cancer
- gastrointestinal malignances
- genitourinary malignancies
- neuro-oncology
- radiation
- CAR T-Cells
- pneumonitis
- Hepatobillary adverse events
- cardiotoxicity
- renal toxicity
- cancer imaging
- microbiome
Editors and Affiliations
-
Professor, Dept. of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
Aung Naing
-
Assistant Professor, Service Chief of Adult Allergy & Immunology, Division of Immunology, Allergy & Retrovirology Baylor College of Medicine and Texas Children’ Hospital, Houston, USA
Joud Hajjar
About the editors
Dr. Aung Naing is a Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing’s research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.
Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children’s Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Women in Clinical Immunology Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in inborn errors of immunity, microbiome in the immunocompromised host, and cancer immunotherapy.
Bibliographic Information
Book Title: Immunotherapy
Editors: Aung Naing, Joud Hajjar
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-3-030-79308-1
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021
Hardcover ISBN: 978-3-030-79307-4Published: 21 December 2021
eBook ISBN: 978-3-030-79308-1Published: 01 January 2022
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 4
Number of Pages: VIII, 447
Number of Illustrations: 9 b/w illustrations, 32 illustrations in colour
Topics: Immunology, Cancer Research